1 / 10

Nesli Basgoz MD Massachusetts General Hospital

Nesli Basgoz MD Massachusetts General Hospital. Pro Early ART Improved immune response to OI/OM OI/OM without good treatment Prevention of next OI/OM Potential for better immune reconstitution with earlier ARVs Prevention of non-infectious complications.

niabi
Download Presentation

Nesli Basgoz MD Massachusetts General Hospital

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nesli Basgoz MD Massachusetts General Hospital

  2. Pro Early ART Improved immune response to OI/OM OI/OM without good treatment Prevention of next OI/OM Potential for better immune reconstitution with earlier ARVs Prevention of non-infectious complications Timing of ARVs in the ICU (or acutely ill with Opportunistic Infections or Malignancies ie OI or OM) Pro Delayed ART • Inability to tell toxicity of OI/OM treatment from ARVs • Making end organ dysfunction worse • Inability to tell OI/OM worsening from ARVs • IRIS • Drug-drug interactions • Malabsorption

  3. ARV during Chemotherapy: What Made This Change Possible? • Development of safer ARVs (non myelosuppressive, less associated with peripheral neuropathy, less associated with multiorgan system dysfunction in patients presenting in fulminant stage of lymphoma or other malignancy • Retrospective and prospective cohort data demonstrating good tolerance and then improved outcomes with early ARV in OM • Similar data in early ARVs in OI

  4. ACTG 5164: Early (<2 week) vs Deferred (> 2 week) ARV in Acute Ois Study Design Opportunistic InfectionTreatmentStarts ImmediateART 48wks 48wks Deferred ART RecommendedStart window -14 0 2 28 42 84 224 Study day 4 – 32 Weeks Randomization Zolopa A, et al. 15th CROI; Boston, MA (2008); Abst. 142.

  5. ACTG 5164 • Majority of OI were PCP • Included ICU patients • Most received corticosteroids for moderate to severe PCP • TB was excluded from the study • Median time to ARV initiation was 12 days • No difference between early vs delayed groups in primary, composite endpoint

  6. A5164: Early ARV Associated with Reduced Risk of AIDS/Death 1.00 n=116 Probability of surviving withoutdeath/new AIDS defining event 0.9 0.8 n=94 0.7 0.6 HR=0.5395%CI (0.25,1.09)p=0.023 0.5 0.4 0.3 Early ART Deferred ART 0.2 0.1 0.0 0 4 8 12 16 20 24 28 32 36 40 44 48 • No difference in rate of virologic suppression • No difference in IRIS (10 immediate, 13 deferred) or chng. ARV • Conclusion: In this population, start ARV within 2 weeks • CAN THIS BE GENERALIZED? Zolopa A, et al. 15th CROI; Boston, MA (2008); Abst. 142.

  7. Timing of ARV in ICU • Sao Paulo, Brazil • Retrospective analysis • 278 ICU admissions ’96 –’06 • Median CD4 <50 • Multivariate logistic regression analysis • Decreased 6-month mortality if ART initiated in the ICU Initiated in the ICU • HR 0.627 (95%CI 0.393-0.999) Initiated in the 1st 4 days of the ICU admission Croda J, et al. IAS Mexico (2008); Abst.3436

  8. Considerations in the ICU • All HIV ICU patients are not alike • Unlikely we will be able to do prospective studies stratifying patients, but more retrospective data should be available • Are there available drugs for Ois and for ARVs which are relatively safe with multiorgan system dysfunction? • Role of rapid diagnostics • Treat appropriate infections • Avoid multiple empiric therapies • Role of adrenal insufficiency and steroids

  9. Ultimately, How Likely is the Patient to Survive without ARVs? • Many scoring systems exist which predict in-ICU mortality • Not validated specifically for HIV ICU patients, but could be • Do no harm, but in many cases, significant treatment-associated risk can be justified by knowing the statistical probability of death without ARVs • This is a calculus that can be understood by most providers and most families

  10. Future Directions • We need to move past treating the sickest ICU patients with the lowest probability of survival without ARV • To prevent infections in the ICU, improved early testing and early ARVs should prevent Icu admission

More Related